Richard J Wennekamp Net Worth

The estimated Net Worth of Richard J Wennekamp is at least 10.5 千$ dollars as of 22 February 2012. Richard Wennekamp owns over 111,965 units of LadRx Corp stock worth over 10,527$ and over the last 20 years Richard sold CYTR stock worth over 0$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Richard Wennekamp CYTR stock SEC Form 4 insiders trading

Richard has made over 2 trades of the LadRx Corp stock since 2004, according to the Form 4 filled with the SEC. Most recently Richard bought 111,965 units of CYTR stock worth 35,829$ on 22 February 2012.

The largest trade Richard's ever made was buying 111,965 units of LadRx Corp stock on 22 February 2012 worth over 35,829$. On average, Richard trades about 7,798 units every 182 days since 2004. As of 22 February 2012 Richard still owns at least 116,965 units of LadRx Corp stock.

You can see the complete history of Richard Wennekamp stock trades at the bottom of the page.

What's Richard Wennekamp's mailing address?

Richard's mailing address filed with the SEC is 11726 SAN VICENTE BLVD, SUITE 650, LOS ANGELES, CA, 90049.

Insiders trading at LadRx Corp

Over the last 21 years, insiders at LadRx Corp have traded over 0$ worth of LadRx Corp stock and bought 3,710,406 units worth 8,711,088$ . The most active insiders traders include Steven A Kriegsman、Scott Bradford Patterson、Max Link. On average, LadRx Corp executives and independent directors trade stock every 177 days with the average trade being worth of 22,531$. The most recent stock trade was executed by Earl W Brien on 14 August 2020, trading 150,000 units of CYTR stock currently worth 39,000$.

What does LadRx Corp do?

Complete history of Richard Wennekamp stock trades at LadRx Corp

LadRx Corp executives and stock owners

LadRx Corp executives and other stock owners filed with the SEC include:

• Steven Kriegsman,
  Chairman of the Board, Chief Executive Officer
• Steven A. Kriegsman,
  Chief Exec. Officer
• John Caloz,
  Chief Financial Officer, Chief Accounting Officer, IR Contact Officer
• John Y. Caloz,
  CFO, Treasurer & Sr. VP
• Louis Ignarro,
  Independent Director
• Joel Caldwell,
  Director
• Earl Brien,
  Director
• Dr. Felix Kratz Ph.D.,
  Sr. VP, Drug Devel.
• Cristina Newman,
  Corp. Sec.
• Terri Stevens,
  Chief Bus. Officer
• Molly Painter,
  Pres of USA and Head of Launch & Commercial Operations
• Molly Carey Poarch,
  Global & U.S. Head of Corp. Communications
• Jennifer K. Simpson,
  Director
• Anita J Chawla,
  Director
• Daniel J Levitt,
  Chief Medical Officer
• Joseph Rubinfeld,
  Director
• Olivia C Ware,
  Chief Commercial Officer
• Douglas Scott Wieland,
  Sr. VP - Drug Development
• Felix Kratz,
  Vice President Drug Discovery
• Herbert H Jr Mcdade,
  
• Alexander L Cappello,
  Director
• Raymond C Jr Carnahan,
  
• Ben Levin,
  Gen.Cnsl/VP Legal Affairs/Secy
• Eric Jay Selter,
  Director
• Cheryl Cohen,
  Director
• Scott Bradford Patterson,
  10% owner
• Marvin R Selter,
  Director
• Richard J Wennekamp,
  Director
• Max Link,
  Director
• David Scott Geyer,
  Sr. V.P. of Manufacturing
• Mitchell K Fogelman,
  Chief Financial Officer
• Jack R Barber,
  Sr VP - Drug Development
• Shi Chung Ng,
  Sr. VP Research & Development
• Matt Natalizio,
  Chief Financial Officer
• Mark Tepper,
  Vice President
• Stephen Snowdy,
  Chief Executive Officer